Follow
Larissa Carnevalli
Larissa Carnevalli
Oncology pRED, Roche
Verified email at roche.com
Title
Cited by
Cited by
Year
Myc depletion induces a pluripotent dormant state mimicking diapause
R Scognamiglio, N Cabezas-Wallscheid, MC Thier, S Altamura, A Reyes, ...
Cell 164 (4), 668-680, 2016
2582016
S6K1 plays a critical role in early adipocyte differentiation
LS Carnevalli, K Masuda, F Frigerio, O Le Bacquer, SH Um, V Gandin, ...
Developmental cell 18 (5), 763-774, 2010
2322010
Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor–positive breast cancer
C Michaloglou, C Crafter, R Siersbaek, O Delpuech, JO Curwen, ...
Molecular cancer therapeutics 17 (5), 908-920, 2018
1502018
mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma
HE Thomas, CA Mercer, LS Carnevalli, J Park, JB Andersen, EA Conner, ...
Science translational medicine 4 (139), 139ra84-139ra84, 2012
1082012
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery
MA Taylor, AM Hughes, J Walton, AML Coenen-Stass, L Magiera, ...
Journal for ImmunoTherapy of Cancer 7, 1-16, 2019
792019
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
LS Carnevalli, C Sinclair, MA Taylor, PM Gutierrez, S Langdon, ...
Journal for immunotherapy of cancer 6 (1), 158, 2018
762018
Translation initiation at non-AUG codons mediated by weakened association of eukaryotic initiation factor (eIF) 2 subunits
NN Hashimoto, LS Carnevalli, BA Castilho
Biochemical Journal 367 (2), 359-368, 2002
622002
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
S Langdon, A Hughes, MA Taylor, EA Kuczynski, DA Mele, O Delpuech, ...
Oncoimmunology 7 (8), e1458810, 2018
502018
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer
A Avivar-Valderas, R McEwen, A Taheri-Ghahfarokhi, LS Carnevalli, ...
Oncotarget 9 (30), 21444, 2018
492018
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response
D Georgopoulou, M Callari, OM Rueda, A Shea, A Martin, A Giovannetti, ...
Nature communications 12 (1), 1998, 2021
452021
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
A Revenko, LS Carnevalli, C Sinclair, B Johnson, A Peter, M Taylor, ...
Journal for Immunotherapy of Cancer 10 (4), 2022
422022
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
TA Proia, M Singh, R Woessner, L Carnevalli, G Bommakanti, L Magiera, ...
Clinical Cancer Research 26 (23), 6335-6349, 2020
372020
Phosphorylation of the α subunit of translation initiation factor-2 by PKR mediates protein synthesis inhibition in the mouse brain during status epilepticus
LS Carnevalli, CM Pereira, CB Jaqueta, VS Alves, VN Paiva, KM Vattem, ...
Biochemical Journal 397 (1), 187-194, 2006
342006
Improved HSC reconstitution and protection from inflammatory stress and chemotherapy in mice lacking granzyme B
LS Carnevalli, R Scognamiglio, N Cabezas-Wallscheid, S Rahmig, ...
Journal of Experimental Medicine 211 (5), 769-779, 2014
282014
Phosphorylation of translation initiation factor eIF2α in the brain during pilocarpine-induced status epilepticus in mice
LS Carnevalli, CM Pereira, BM Longo, CB Jaqueta, M Avedissian, ...
Neuroscience letters 357 (3), 191-194, 2004
252004
Metabolic control by S6 kinases depends on dietary lipids
TR Castañeda, W Abplanalp, SH Um, PT Pfluger, B Schrott, K Brown, ...
PLoS One 7 (3), e32631, 2012
242012
Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML
S Basilico, X Wang, A Kennedy, K Tzelepis, G Giotopoulos, SJ Kinston, ...
Nature Communications 11 (1), 1407, 2020
172020
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
FC Martins, DL Couturier, I De Santiago, CM Sauer, M Vias, M Angelova, ...
Nature Communications 13 (1), 6360, 2022
152022
Modeling dose and schedule effects of AZD2811 nanoparticles targeting aurora B kinase for treatment of diffuse large B-cell lymphoma
N Floc'h, S Ashton, D Ferguson, P Taylor, LS Carnevalli, AM Hughes, ...
Molecular Cancer Therapeutics 18 (5), 909-919, 2019
152019
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer
A Harrod, CF Lai, I Goldsbrough, GM Simmons, N Oppermans, DB Santos, ...
Oncogene 41 (44), 4905-4915, 2022
112022
The system can't perform the operation now. Try again later.
Articles 1–20